Zhengyun Y. Zou

321 Zhongshan Road
Nanjing, 210008, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 48 publications

A retrospective study of PD-1 monoclonal antibody combined with nab-paclitaxel plus bevacizumab in the treatment of advanced malignant melanoma

A retrospective study of PD-1 monoclonal antibody combined with nab-paclitaxel plus bevacizumab in the treatment of advanced malignant melanoma

Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]

Published: May 05, 2026

In situ blockade of TNF-TNFR2 axis via oncolytic adenovirus improves antitumor efficacy in solid tumors.

In situ blockade of TNF-TNFR2 axis via oncolytic adenovirus improves antitumor efficacy in solid tumors.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: January 24, 2025

C-Reactive Protein to Lymphocyte Ratio (CLR) and Lactate Dehydrogenase to Albumin Ratio (LAR) as Prognostic Biomarkers in Acral Melanoma: Association With Tertiary Lymphoid Structures and Immune Cell Infiltration.

C-Reactive Protein to Lymphocyte Ratio (CLR) and Lactate Dehydrogenase to Albumin Ratio (LAR) as Prognostic Biomarkers in Acral Melanoma: Association With Tertiary Lymphoid Structures and Immune Cell Infiltration.

Journal: Cancer medicine

Published: December 12, 2024

Socioeconomic status correlates with clinical outcomes in patients with acral melanoma.

Socioeconomic status correlates with clinical outcomes in patients with acral melanoma.

Journal: Frontiers in public health

Published: September 13, 2024

In situ blockade of TNF-TNFR2 axis via oncolytic adenovirus improves antitumor efficacy in solid tumors.

In situ blockade of TNF-TNFR2 axis via oncolytic adenovirus improves antitumor efficacy in solid tumors.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: February 21, 2024

A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma.

A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 22, 2023

Acidity-targeting transition-aided universal chimeric antigen receptor T-cell (ATT-CAR-T) therapy for the treatment of solid tumors.

Acidity-targeting transition-aided universal chimeric antigen receptor T-cell (ATT-CAR-T) therapy for the treatment of solid tumors.

Journal: Biomaterials

Published: November 22, 2023

Trauma plays an important role in acral melanoma: A retrospective study of 303 patients.

Trauma plays an important role in acral melanoma: A retrospective study of 303 patients.

Journal: Cancer medicine

Published: November 16, 2023

Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects.

Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects.

Journal: Epigenomics

Published: January 05, 2023

Therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in unresectable pancreatic cancer.

Therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in unresectable pancreatic cancer.

Journal: Frontiers in oncology

Published: August 09, 2022

Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study.

Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study.

Journal: BMC cancer

Published: July 20, 2022

AGIG Chemo-Immunotherapy in Patients With Advanced Pancreatic Cancer: A Single-Arm, Single-Center, Phase 2 Study.

AGIG Chemo-Immunotherapy in Patients With Advanced Pancreatic Cancer: A Single-Arm, Single-Center, Phase 2 Study.

Journal: Frontiers in oncology

Published: April 10, 2021

Showing 1-12 of 48

Last Updated: 09/26/2026